Document is current
Any future updates will be listed below
-
Authors
Carrette, Florent
Demaria, Olivier
Andre, Pascale
Vallier, Jean-Baptiste
Van, Mélanie Le
Galluso, Justine
Baron, William
Bigenwald, Camille
Vétizou, Marie
Remark, Romain
Thibult, Marie-Laure
Bonnafous, Cecile
Morel, Yannis
Quaratino, Sonia
Paturel, Carine
Vivier, Eric
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05086315 at ClinicalTrials.govnct06088654 at ClinicalTrials.govDocuments that mention this clinical trial
1083 Preclinical characterization of IPH6501: a novel IL2v-armed tetraspecific NK cell engager targeting CD20 in relapsed or refractory B cell non-Hodgkin lymphoma subtypes and post-CAR-T therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1083
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
https://doi.org/10.1200/jco.2023.41.16_suppl.7005
Documents that mention this clinical trial
1083 Preclinical characterization of IPH6501: a novel IL2v-armed tetraspecific NK cell engager targeting CD20 in relapsed or refractory B cell non-Hodgkin lymphoma subtypes and post-CAR-T therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1083
A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.tps7095
- License Information
